Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL)
Recalled by McKesson
Class II — moderate
Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
McKesson has recalled Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on July 8, 2026 and was initiated on June 10, 2026. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), with approximately 74 units affected. The company behind the recall is McKesson, based in Irving, TX. The FDA describes the product as: “Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 01…”
Why was Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL) recalled?
According to the FDA, the stated reason for the recall is: “Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.”
What should you do?
If you think you may have bought Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), compare it against the product description and identifying codes (Lot #: CB0046, Exp. Date 06/2027) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact McKesson or your local health authority.
About this recall
This recall was distributed in TX. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Who this recall affects
This recall matters to anyone who bought Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL). Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.
Distribution listed in the notice: Nationwide within the United States.
How to check whether you have it
On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.
Compare what you find against the identifying details in this recall: Lot #: CB0046, Exp. Date 06/2027
What to do if you already bought it
Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.
Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.
If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.
Full recall details
- Status
- Ongoing
- Date reported
- July 8, 2026
- Recall started
- June 10, 2026
- Distributed in
- TX
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL) recalled?+
According to the FDA: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment in…
How serious is this recall?+
Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
What should I do if I have Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL)?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0714-2026. Information last synced from the FDA on July 27, 2026.